Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 713Pancreatic Neoplasms 500Carcinoma, Hepatocellular 333Colonic Neoplasms 282Stomach Neoplasms 278Rectal Neoplasms 236Esophageal Neoplasms 198Neoplasms 194Liver Neoplasms 169Neoplasm Metastasis 164Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 111Cholangiocarcinoma 91Ovarian Neoplasms 87Lung Neoplasms 85Gastrointestinal Neoplasms 80Melanoma 76Gastrointestinal Stromal Tumors 68Adenocarcinoma Of Esophagus 64Adenocarcinoma 62Prostatic Neoplasms 59Biliary Tract Neoplasms 58Carcinoma, Renal Cell 56Sarcoma 54Head and Neck Neoplasms 54Urinary Bladder Neoplasms 51Gallbladder Neoplasms 49Barrett Esophagus 49Bile Duct Neoplasms 47Anus Neoplasms 47

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian × Gastrointestinal × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡